Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
US Army
US Department of Justice

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,671,192

« Back to Dashboard

Title:Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs
Abstract: Synthesis methods suitable for large scale manufacture of the A.sub.2A-adenosine receptor agonist (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyrazol-4-yl)-N-methylcarboxamide and precursors thereof.
Inventor(s): Zablocki; Jeff (Mountain View, CA), Elzein; Elfatih (Fremont, CA)
Assignee: Gilead Palo Alto, Inc. (Foster City, CA)
Filing Date:May 17, 2007
Application Number:11/750,295
Claims:1. A method of synthesizing (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyrazol-4-yl)-N-methylcarboxamide ##STR00025## by contacting a compound of the formula (4): ##STR00026## and wherein the reaction is with aqueous methylamine at a temperature of approximately 2.5-7.5.degree. C. conducted in a sealed pressure reactor.

2. The method of claim 1, further comprising wherein the product is isolated by (a) degassing under vacuum at not more than 35.degree. C. to remove excess methylamine, (b) releasing the vacuum and cooling to 0-5.degree. C. for approximately 15-minutes to an hour, (c) filtering the slurry thus formed, (d) washing the contents of the filter with water followed by ethanol, and (e) drying the solid that remains under vacuum at a temperature that does not exceed 40.degree. C.

3. The method of claim 2 further comprising wherein the (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyrazol-4-yl)-N-methylcarboxamide end product is further purified by (i) dissolving the dried solid from step (e) of claim 2 in a solvent, (ii) filtering any solid impurities from the solution, (iii) rinsing with additional solvent, (iv) adding solution to purified water that is maintained at approximately 78-88.degree. thereby forming a slurry, (v) stirring the slurry, (vi) cooling the slurry, (vii) filtering, (viii) washing the contents of the filter with water followed by ethanol, and (ix) drying the solid that remains under vacuum at a temperature that does not exceed 40.degree. C.

4. The method of claim 3, further comprising wherein the solvent of steps (i) and (iii) is dimethylsulfoxide.

5. The method of claim 4, further comprising wherein the residual water content in the final product is not more than 5.5% and the residual ethanol is not more that 2000 ppm.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Fish and Richardson
Boehringer Ingelheim
US Army
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.